Glutamate (2)
Multiple sclerosis (2)
Myelin oligodendrocyte glycoprotein (2)
Obesity (2)
Adherence (1)
adipose tissue thickness (1)
Albumin (1)
Amyloid (1)
Ankylosing spondylitis (1)
anthropometry (1)
associated disease (1)
ataxia (1)
atypical demyelinating diseasesi MOGAD (1)
Azathioprine (1)
Biomarker (1)
Body mass index (1)
calcification (1)
Calcium (1)
carpal tunnel syndrome (1)
Carpal tunnel syndrome (1)
Choroid plexus (1)
Cladribine (1)
diagnostic algorithm (1)
diagnostic delay (1)
Disability (1)
Disease activity (1)
Disease-modifying therapies (DMTs) (1)
Efficacy (1)
Excitotoxicity (1)
exome sequencing (1)
Expanded disability status scale (EDSS) (1)
familial (1)
Fibrinogen (1)
Fibrinogen/Albumin ratio (1)
Fingolimod (1)
Follow-on drug (1)
gender (1)
Generic fingolimod (1)
genetic (1)
genetics (1)
Hepatotoxicity (1)
heterogeneity (1)
Immunoglobulin IgG index (1)
Inflammation (1)
Ischemia-reperfusion (1)
index of suspicion (1)
ischemic stroke (1)
late-onset Pompe disease (1)
ligamentum flavum (1)
Liver function tests (LFTs) (1)
Median nerve (1)
MOG (1)
MOGAD (1)
myelin oligodendrocyte glycoprotein antibody associated disease (1)
myelin oligodendrocyte glycoprotein antibody disease (1)
N-methyl-d-aspartate receptor (1)
Oligoclonal band number (1)
optic neuritis (1)
osteopontin (1)
outcome (1)
polyneuropathy (1)
Rat (1)
Real-world data (1)
Relapsing-remitting multiple sclerosis (RRMS) (1)
Restless Legs Syndrome (1)
Rituximab (1)
Safety (1)
Satisfaction (1)
semaphorin 3A (1)
semaphorin 3F (1)
semaphorin 4A (1)
semaphorin 4D (1)
semaphorin 7A (1)
Subcutaneous Fat (1)
tDCS (1)
Transaminases (1)
Transcranial direct current stimulation (1)
Traumatic brain injury (1)
treatment (1)
Treatment (1)
Treatment transition (1)
Turkey (1)
Washout period (1)
whole‐ (1)